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ABSTRACT 
Introduction 
Bilateral mammoplasty (BM) can optimise oncological safety and aesthetic outcomes in 
women with large or ptotic breasts whose tumour to breast volume ratio or tumour location 
pose a challenge to standard breast conserving therapy (BCT) and for whom mastectomy 
(with or without reconstruction) may be the only alternative.  
Methods 
We undertook a comprehensive analysis of surgical outcomes (complications according to 
the Clavien Dindo classification), acute radiation morbidity (Radiation Therapy Oncology 
Group classification), oncological outcomes, and patient satisfaction (BREAST-Q 
questionnaire) in women who underwent BM for breast cancer (BC) from June 2009-
November 2014. 
Results 
168 women were included. Median age was 55 years (range: 33-84) and median tumour size 
at imaging 35mm (range:0-170). Median specimen weight was 242g (range: 39-1824). The 
wise pattern technique was used in 87.5% of procedures. At least one complication occurred 
in 68 (40.5%) women most of which were Clavien Dindo grade 1. Grade 3 complications 
were infrequent (8.9 %) but occurred mainly on the therapeutic mammoplasty (TM) side 
(p<0.05). Complications were associated with higher BMI, specimen weight and longer time 
to radiotherapy (p<0.05).  
Median follow-up was 37 months (range: 13-77). Local recurrence occurred in 3(1.8%), 
distant metastases in 5(3.0%), and 10(6.0%) women have died. Tumour size 4 cm was 
associated with a higher rate of distant recurrence and margin involvement (p<0.05). The 
median score for ‘satisfaction with breasts’ was 77 (range: 0-100).  
Conclusions 
This study provides concurrent data on surgical, oncological and patient-reported outcomes. 
It offers evidence that BM is an effective treatment for breast cancer in large- or ptotic-
breasted women, particularly if mastectomy is the alternative. 
 
INTRODUCTION 
Oncoplastic breast surgery was established in the 1990s to facilitate tumour resection without 
compromising aesthetic appearance1; 2; 3. Therapeutic mammoplasty was first described by 
Clough et al. in 1990 in a study of patients undergoing breast reduction surgery to remove a 
lower pole cancer4. Therapeutic mammoplasty has become a widely available option and is 
applied predominantly to large-breasted women.  The estimated prevalence of macromastia in 
women treated with breast-conserving therapy (BCT) (surgery and radiotherapy) is up to 
40%5; 6. Criteria defining macromastia are not universally agreed, but published data suggest 
that the most accepted are cup size≥D or a bra size≥40 inches5; 7 
A patient with large or ptotic breasts whose tumour to breast volume ratio and/or tumour 
location poses a challenge to standard BCT may benefit from therapeutic mammoplasty8; 9; 10; 
11; 12; 13; 14; 15; 16; 17; 18. Up to 30% of patients after BCT have poor cosmetic results due to 
surgery and irradiation, which may result in breast distortion and deformities that are 
challenging to correct19; 20.  Aesthetic outcome after BCT is affected by breast size, and 
unfavourable results are more common in women with macromastia as they experience more 
asymmetry, retraction and late radiation changes than small-breasted women7; 10; 11; 21. Thus 
women with large breasts who are at increased risk of acute radiotherapy toxicity may also be 
candidates for therapeutic mammoplasty even with a favourable tumour to breast volume 
ratio. 
The aim of this study was to analyse outcomes after BM from a single large centre 
concurrently reporting on surgical, oncological and aesthetic outcomes, notably including 
patient satisfaction. 
PATIENTS AND METHODS 
All patients who underwent BM for breast cancer from June 2009 to November 2014 were 
included in this retrospective review. At our institution, oncoplastic breast surgeons offer BM 
to suitable patients (cup size≥D or moderate to significant of ptosis), performing either 
immediate or delayed symmetrisation. The reduction technique was selected by the surgeon 
after discussion with the patient about her acceptance of scars, the breast size, the degree of 
ptosis and tumour size and location.  Patients who had delayed symmetrisation were 
included, provided that both operations were performed during the study period. The operated 
breasts were divided into therapeutic mammoplasties (TM) and contralateral symmetrising 
mammoplasties (SM). 
Data was collected from a prospectively maintained database and electronic medical records 
and recorded in Microsoft Excel (Microsoft Corp, Redmond, Wash.). Preoperative data 
included patient demographics, smoking history and co-morbidities (obesity, diabetes) and 
tumour characteristics (largest preoperative size at imaging, location, pathological details) 
and any neoadjuvant treatment. Surgical technique for each breast and timing of contralateral 
symmetrisation, nipple-areola complex removal and either immediate or delayed nipple 
reconstruction were recorded. Postoperative histopathological details included tumour 
features, resection (index breast) and reduction (contralateral breast) specimen weights, and 
nodal involvement. Adjuvant endocrine therapy, chemotherapy and radiotherapy and time to 
commencing the first adjuvant treatment were also recorded. 
 
Surgical and radiation outcomes 
Surgical outcome measures included complications within 30 days of surgery, grouped 
according to the Clavien Dindo Classification22 (Table 1). Patients were divided into two 
groups according to whether postoperative complications occurred or not, and compared for 
preoperative, surgical and postoperative characteristics including length of hospital stay, 
readmission within 30 days, delay (>6 weeks post-operatively) in starting adjuvant treatment 
and requirement for revision surgery. Radiation skin reactions were recorded according to the 
Radiation Therapy Oncology Group (RTOG) Scoring System for acute radiation morbidity in 
grades I to IV.23; 24  
Oncological outcomes 
Oncological outcomes comprised rates of radial margin involvement, margin re-excision, 
additional radiotherapy boost, conversion to mastectomy, loco-regional recurrence, distant 
recurrence and death. For all of the study period a margin was considered negative if greater 
than 1mm from invasive cancer and 2mm from DCIS. 
Patient Satisfaction 
Patient satisfaction was evaluated using a validated questionnaire (BREAST-Q Breast 
Conserving Therapy Module)25. Patients who moved abroad, developed distant disease or 
went on to have mastectomy were excluded. A score for each of the nine domains within the 
questionnaire was derived and then transformed to a scale of 0-100 according to the 
BREAST-Q protocol. Higher scores equate to more favourable outcomes. Patients were 
divided into less and more satisfied according to whether their score for ‘satisfaction with the 
breasts’ domain fell above or below the median. Differences in patient and tumour 
characteristics were evaluated between these two groups. We compared satisfaction with 
breast symmetry in patients who had immediate versus delayed symmetrisation, and 
satisfaction between patients who had no nipple reconstruction and the rest of the cohort.  
Statistical Analysis 
The mean and standard deviation were calculated for all parametrically-distributed variables, 
while the median and the range of values were calculated for non-parametric variables. 
Fisher’s exact test was applied for categorical data, Student’s t test for continuous normally 
distributed data and Mann-Whitney test for non-parametric data. 
RESULTS 
During the period reviewed, 168 patients underwent BM for cancer. Of 336 procedures, 177 
were therapeutic (9 women had bilateral BC) and 159 symmetrising (9 of these had incidental 
cancer but for the purpose of analysing outcomes, they have been classified by intention to 
treat). 155 patients underwent synchronous bilateral surgery, while 13 underwent unilateral 
therapeutic mammoplasty followed by a delayed contralateral symmetrisation after a median 
of 14 months (range: 5-30). The median follow-up from index surgery was 37 months (range: 
13-77). 
The median age at primary surgery was 55 years (range: 33-84), and median body mass index 
(BMI) was 29.3 kg/m2 (range: 19.2-49.2). Patient and tumour characteristics are summarized 
in Table 2. The wise pattern technique was used in 87.5% (294/336) of procedures. In 56.3% 
(189/336) of these the inferior pedicle was chosen as single pedicle, or as inferocentral when 
a bipedicle. The remaining breast reduction techniques included: 18 (5.3%) round block, 13 
(3.9%) short scar periareolar inferior pedicle, 7 (2.1%) lateral, 2 (0.6%) omega, 2 (0.6%) 
vertical mammoplasty. The nipple-areola complex was removed in 49 breasts (14.6%), 
generally as a planned, oncological procedure, with 6 (1.8%) breasts having immediate and 
12 (3.6%) delayed nipple reconstruction with C-V flaps, while the remaining patients 
declined further surgery. The median therapeutic resection specimen weight was 242g (range: 
39-1824), while the median symmetrising reduction specimen weight was 260g (range: 34-
1700). Reduction specimen pathology identified incidental malignancy in the symmetrising 
specimen in 9 (5.4%) patients, all being DCIS ranging from 2 to 65 mm.  
Of the 168 women, 4 converted to mastectomy, 6 had no adjuvant therapy and in 20 adjuvant 
data were not available. Of the remaining 138 (82.1%), 84 underwent radiotherapy, 50 
chemotherapy and 4 endocrine therapy as first adjuvant treatment. 
The median time from surgery to first adjuvant treatment was 51.5 days (range: 21-153), 57 
days (range: 30-153) for radiotherapy and 39.5 days (range: 21-81) for chemotherapy (Figs. 1 
and 2). 
Surgical and Radiation Outcomes 
At least one complication was recorded in 68 (40.5%) women and 87 (25.9%) breasts (Table 
3). Multiple complications of different grades were reported as separate events so for 
simplification we stratified women and breasts according to the highest grade complication 
recorded.    
Grade 1 complications were the most frequent (23.8% of patients and 16.3% of breasts), 
while grade 2 or 3 complications affected only 8.3% of patients. BMI and reduction specimen 
weight were higher in patients with complications (p values: 0.0001 and 0.0028 respectively) 
regardless of whether the indication for surgery was therapeutic or symmetrising. The only 
significant difference between TM and SM groups in terms of complication rate was the 
occurrence of grade 3 complications, which were more frequent in the TM group (p <0.05). 
Furthermore TM complications resulted in a significantly increased time to radiotherapy (RT) 
with a median of 77 days (range: 33-153) compared with 55 days (range: 30-94) for no TM 
complications (p value: 0.03). Contralateral SM complications would not delay RT.  Median 
time to chemotherapy showed no significant difference (p value: 0.285) between those who 
experienced complications (regardless of which side) and those who did not. 
 
The median hospital stay was 1 night (range: 0-6). Unplanned readmission (<30 days after 
primary surgery) was required in 6 (3.6%) patients because of complications (3 haematomas,  
1 nipple necrosis, 1 infection requiring surgical revision (all Clavien 3b) and one infection 
requiring intravenous antibiotics (Clavien 2). 
Acute skin reactions after radiation were reported in 39 (23.2%) patients. Acute radiation 
morbidity was classified in four grades according to RTOG scoring system, 24 (14.3%) 
patients experiencing grade 1 morbidity (follicular, faint or dull erythema, dry desquamation), 
11 (6.5%) patients grade 2 (tender or bright erythema, patchy moist desquamation, moderate 
erythema), 4 (2.4%) patients grade 3 (confluent moist desquamation, other than skin folds, 
pitting oedema). No grade 4 skin reactions (ulceration, haemorrhage, necrosis) were seen. 
 
Oncological outcomes 
Radial resection margins were involved in 20 (11.3%) of the 177 breasts, of which four 
(2.3%) converted to mastectomy and eight (4.5%) were re-excised. Six (involved by DCIS 
alone) were treated by tumour bed RT boost and two patients had metastases at diagnosis. A 
further 4 patients underwent mastectomy at a later date, 3 for local recurrence (1.8%) and one 
after a BRCA mutation was discovered. At a median follow-up of 37 months, three (1.8%) 
have had local recurrence, five (3.1%) were alive with distant metastases and ten (6.1%) 
women had died of BC. 
Patients with a tumour size of > 4 cm at diagnosis had a significantly higher risk of distant 
recurrence and margin involvement than those with smaller tumours (<4cm) (p value <0.05). 
Patient Satisfaction 
The 137 eligible patients were sent the BREAST-Q questionnaire by post and 72 (52.6%) 
replied. Results are shown in Table 4. The median score for patient ‘satisfaction with breasts’ 
was 77 (range: 0-100), therefore the 34 with a score <77 were considered less satisfied, while 
the 38 whose score was ≥77, were considered more satisfied. Between-group comparisons 
showed no significant differences in clinico-pathological data, surgical or oncological 
outcome measures. Patients who had no nipple reconstruction showed no significant 
difference in satisfaction with the breasts compared to the rest of the cohort (p value: 0.16). 
As the development of late asymmetry is often the rationale for avoiding immediate 
symmetrisation, we specifically analysed the question “How satisfied are you with how much 
your breasts look the same?”. There was no significant difference between the immediate and 
delayed symmetrisation groups (p value>0.05).  
 
DISCUSSION 
Therapeutic mammoplasty is a common keyword in the recent literature on surgical treatment 
of breast cancer, yet the definition is controversial. Some authors count every breast-
conserving procedure involving parenchymal mobilisation as a therapeutic mammoplasty, 
while for others therapeutic mammoplasty is limited to the application of breast reduction 
techniques to breast oncological surgery. According to the former definition, Fitoussi et al. 
published the largest case series in 2010, combining bilateral or unilateral application of 
plastic surgical techniques to oncological excisions 26. According to Clough’s definition of 
oncoplastic surgery, reduction mammoplasty techniques which already exist in plastic 
surgery and combine breast reduction and tumour resection are known as level II oncoplastic 
resections; the volume excised means the majority of these require contralateral 
symmetrisation27. 
We followed Clough’s definition, applying breast reduction techniques to large or ptotic 
breast and ours is one of the largest reported series of immediate BM for cancer. While the 
resection volumes are not large by comparison with patients undergoing mammoplasty for 
symptoms of macromastia, the median specimen weight of 242g (range: 39-1824g) is 
substantially larger than the median resection weight of (32.5g (range: 9-346g) in a 
contemporary series of standard breast conservation in our institution. Grubnik et al. included 
any oncoplastic technique involving parenchymal and nipple-areola complex displacement. 
Their mean resection weight was smaller (237g compared with our mean of 321.1g)9. Egro et 
al. have published data on 160 patients who underwent reduction mammoplasty, 96% being 
bilateral. They showed that the 117 immediate reduction mammoplasty patients had lower 
morbidity, fewer procedures and good aesthetic outcomes when compared to delayed 
procedures performed after radiotherapy28.  
In addition to the issues of definition, detailed data evaluating these procedures are still 
limited. McIntosh et al. reviewed all studies of “therapeutic mammoplasty” in 2012, finding 
no consistency in reporting indications or outcome29. Later series show the same limitations 6; 
9; 28; 30; 31; 32; 33; 34; 35. Just as Potter et al.36 outlined a core dataset for reporting on breast 
reconstruction, so a similar structure should be followed for oncoplastic breast conservation, 
namely concurrent reporting of oncological parameters, and surgical and patient-reported 
outcome measures. We reported on all of these outcome measures and, at the time of writing, 
we are the only group to have done so. 
Furthermore, to standardise reporting we used validated and well-known systems of 
classification. The Clavien Dindo Classification of surgical complications is therapy-oriented 
and has been developed to allow comparison of complications arising from different surgical 
procedures22. Similarly, the RTOG grading is recognised as the most clinically useful method 
of documenting skin reaction; it is widely used in the literature on acute radiotherapy 
complications23; 37. Finally, the Breast Conserving Therapy (BCT) module of the BREAST-Q 
questionnaire is the latest module in a suite of validated tools for patient-reported outcomes 
and is here utilised for the first time after therapeutic mammoplasty. Previous studies of 
therapeutic mammoplasty reported results from non-validated tools, or used the Breast 
Reduction Module of the BREAST-Q which was created for cosmetic surgery28; 29; 38. We 
chose the BCT Module to assess patient satisfaction with the breast and the adverse effects of 
radiation which are breast cancer-specific domains of this module25; 39. 
Surgical outcomes 
Despite BM being more complex surgery than standard BCS, we reported a short length of 
hospital stay (median: 1 night) and a low rate of readmission within 30 days (3.6%). We 
found a complication rate of 16.3% of breasts, which is comparable to previous series of 
oncoplastic breast surgery8; 40. Benchmarking against other reports using the Clavien Dindo 
system, our complication rates are within the reported range reported by Panhofer et al. for 
example. Our BM cohort resembles their mastectomy group (24.2% grade 1, 11.7% grade 2 
and 3.9 % grade complications) more closely than their BCT group (4.8% grade 1, 7.3% 
grade 2, 4.8% grade 3 and 0.3% grade 4), which included both wide local excisions and 
oncoplastic procedures22. 
The only significant difference between therapeutic and symmetrising procedures in our 
series was in the incidence of grade 3 complications, but the number of cases was too small to 
draw meaningful conclusions. Grade 1 complications were the commonest regardless of 
whether the surgical intent was therapeutic or symmetrizing. Even though these are minor 
complications from the surgical perspective, their duration affects patient quality of life and 
may result in a delay to adjuvant treatment to a greater extent than a grade 3 complication, 
which can be solved by a brief intervention (e.g. delayed wound healing versus postoperative 
haematoma). 
Several studies have reported no significant delay in adjuvant treatment after oncoplastic 
procedures and our data confirm this for adjuvant chemotherapy, showing no difference in 
the time from surgery to chemotherapy between patients with and without complications (p 
value:0.285) 35; 41; 42. Conversely, the time from surgery to radiotherapy was statistically 
significantly longer when complications occurred, perhaps due to the fact that complete 
wound healing is thought to be mandatory before radiation (Figs.1-2). Current UK National 
Institute for Health and Clinical Excellence guidelines43 state that adjuvant therapy should be 
commenced as soon as clinically possible within 31 days of completion of surgery, yet the 
optimum time interval between surgery and radiation has not been established. Given that 
delayed wound healing was the most common complication, new solutions such as pre-
emptive negative pressure wound therapy on the incised wound could be considered 44. 
Acute radiation morbidity is an important cause of distress, especially for large-breasted 
patients. In this series of BM, the RTOG grades were comparable to data reported for wide 
local excision only, perhaps because of better radiation dose distribution24; 45. 
  
Oncological outcomes 
There is on-going debate about whether oncological outcome after therapeutic mammoplasty 
should be compared with patients undergoing mastectomy or standard BCT. Mansell et al. 
recently argued in favour of comparison with mastectomy46. Certainly, our patients with a 
median tumour size of 35mm, 74.6% of tumours being pT2-T3 and the macrometastasis node 
positive rate of 32.5% are more in line with the mastectomy cohort presented in that study 
(50.9% pT2-T3 tumours, 46.8% positive nodes). The 3.1% distant metastasis and 6.1% breast 
cancer related mortality rates, are also in line with previous studies with similar or longer 
follow-up (12-14% and 7-10% respectively)29 notwithstanding 47.6% of our patients had 
tumours larger than 4 cm which was associated with higher rates of distant recurrence and 
margin involvement in our series. However if the tumour characteristics are matched then, as 
described by De Lorenzi et al.47, comparison with standard BCS is appropriate. They 
included volume displacement and replacement techniques (fasciocutaneous flaps, implant) 
and did not give a mean specimen weight, so direct comparison with our cohort is not 
possible. 
The local recurrence rate in our series was 1.8% at a median follow up of 37 months which is 
within the range reported in many series of breast-conserving treatment for more favourable 
disease48. Like Bamford et al35, but unlike most previous series9; 49; 50; 51; 52; 53, we also 
included multifocal/multicentric and larger tumours which does not seem to have adversely 
affected local control. While we agree with Mansell et al. that the cohort is higher risk than 
most standard BCT series, if the local recurrence rates are so low, then equivalence with 
standard BCT, in terms of local control, remains a valid goal (46).  
Patient-reported outcomes 
The key PROMs in this study were satisfaction with breasts and adverse effects of 
radiotherapy. The median value of 77 (range: 0-100) for ‘satisfaction with the breast’ is 
comparable both to previous studies and to a cohort of women who underwent standard BCT 
at our institution54. The median score of 89 for ‘adverse effect of radiation’ (range: 73-100) is 
slightly better than our BCT population, suggesting that the decrease in breast size has a 
positive effect. In most series of BREAST-Q, satisfaction with information and personnel are 
very high, and this is mirrored in our results. Results for physical, psychological and sexual 
wellbeing are also in line with other series. When compared with the UK National 
Mastectomy and Reconstruction Audit in 2011, this cohort of therapeutic mammoplasty 
patients has a higher physical wellbeing score (75.9) than those who underwent mastectomy 
and immediate reconstruction with implant and/or pedicled flap (73-75), and a similar score 
to those who underwent autologous free flap reconstruction (76)55. Sexual wellbeing had the 
lowest response rate and a median score of only 54.5. Again this is seen in other studies and 
highlights a side effect of the disease and therapy which is often underestimated and under-
reported by patients. 
This was a non-randomised single centre study with moderate follow-up. We did not directly 
assess cosmetic outcome, as we focused on the patient’s perception of the aesthetic results 
which is often different from the clinician’s view. Our evaluation of patient satisfaction is 
limited by a response rate of 52% to the BREAST-Q questionnaire. This may be because, at a 
median follow up of 37 months, women’s lives have become busy with non-healthcare 
activities. Sending a paper questionnaire and requiring return by post may have limited 
uptake and introduced a source of bias. We advocate routine collection of PROMs data at 
strategic points along the patient’s treatment pathway. 
The future for BM 
If the indications for BM can be more clearly defined and outcomes evaluated prospectively 
against a truly comparable cohort of women it may be possible to demonstrate that BM offers 
significant additional benefit over the alternatives (standard breast-conservation for some, 
mastectomy and reconstruction for others). It is difficult to recruit women into randomised 
controlled trials in surgery as these often involve subjective and patient-driven choices. 56 
However prospective collaborative national audits are providing useful data in the breast 
surgery setting 57; 58 and a study of therapeutic mammoplasty with a similar design is in the 
planning phase in the UK58.  
 
Conclusion 
This study provides concurrent data on surgical, oncological and patient-reported outcomes 
after BM. BM achieved surgical and oncological outcomes within published ranges with high 
levels of patient satisfaction.  Despite some limitations, this study offers further evidence that 
BM is a safe and effective treatment for breast cancer and may allow some women the 
opportunity to avoid mastectomy. 
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Table 1 Clavien Dindo Classification adapted for breast cancer26 
 
 
 
  
GRADE Definition 
Grade 1 Any deviation from the normal postoperative course without the need for pharmacological treatment or 
surgical or radiological interventions. Allowed drugs: antiemetics, antipyretics, analgesics, diuretics, 
electrolytes and physiotherapy. 
e.g. seroma/haematoma not requiring drainage, minor skin necrosis, delayed wound healing 
Grade 2 Complications requiring pharmacological treatment with drugs other than such allowed for grade 1. 
(e.g. wound infection). 
Grade 3 Complications requiring intervention 
3a: not under general anaesthesia 
e.g. seroma/haematoma which were drained under US guidance, skin necrosis undergoing debridement 
3b: under general anaesthesia  
e.g.  major skin necrosis, wound infection requiring debridement, bleeding 
Grade 4 Life-threatening complication 
Grade 5 Death 
Table 2 Patient and Tumour Characteristics 
Population 
 
Total number of patients 
Number (%) or 
Median(range) 
168 
Mean Age ± SD (years) 
Overweight (BMI 25-30kg/m2) 
Obesity (BMI>30kg/m2) 
Diabetes 
Smoking history (current /ex smokers) 
55(33-84) 
55(32.7) 
79(47.0) 
5(3.0) 
74(44.0) 
Ethnicity 
White 
Black 
Asian 
Other 
125(74.4) 
13(7.7) 
10(6.0) 
20(11.9) 
Tumour Characteristics 
Total number of affected breasts 
Median preoperative tumour size  (range), mm  
Median pathological tumour size  (range), mm  
177 
35(0-170) 
35(0-136) 
Tumour Location  
Upper outer quadrant 
Central 
Lower outer quadrant 
Upper inner quadrant 
Lower inner quadrant 
Multicentric 
Multifocal  
87(49.2) 
24(13.6) 
23(13.0) 
19(10.7) 
17(9.6) 
7 (4.0) 
23(13) 
  
Tumour pathology 
DCIS 
IDC+DCIS 
IDC 
ILC 
Mixed IDC/ILC features 
Paget’s disease 
Other (metaplastic, mucinous cancer) 
14(7.9) 
98(55.4) 
31(17.5) 
25(14.1) 
4(2.3) 
2(1.1) 
3(1.7) 
Grade 1 
Grade 2 
Grade 3  
16(29.6) 
67(43.5) 
71(46.1) 
ER+ 
PR+ 
Her2+ 
139(78.5) 
118(66.7) 
24(13.6) 
ALND 
SLNB 
No axillary procedures 
 
59(33.3) 
113(63.9) 
5(2.8) 
 
pN0 
pN1mic 
pN1 (1-4) 
pN2(4-9) 
pN3(>9) 
108(62.8) 
8(4.7) 
40(23.2) 
10(5.8) 
6(3.5) 
 
Other treatment  
Neoadjuvant chemotherapy 
Adjuvant chemotherapy 
Endocrine therapy 
Radiotherapy 
57 (33.9) 
56(33.3) 
123(73.2) 
153(91.1) 
 
 
 
  
Table 3 Complication Rates 
Complications TM (%) SM (%) p value 
Total breasts 177 159  
Clavien Dindo Grade 1 36(20.3) 39(24.5) 0.362 
Clavien Dindo Grade 2 15 (8.5) 7(4.4) 0.185 
Clavien Dindo Grade 3 12(6.8) 3(1.9) 0.035 
of which 3a 4(2.3) 0(0) 0.124 
of which 3b 8(4.5) 3(1.9) 0.226 
Total complications 63 49 0.417 
 
 
Table 4 Patient Reported Outcomes 
BREAST-Q subscale Median(IQR) Mean No answer 
Satisfaction with breasts 77 (57-93.25) 73.5 0 
Adverse Effects of Radiation 89 (73-100) 84.2 1 
Psychological Wellbeing 76 (63-100) 75.3 0 
Sexual Wellbeing 52 (40-64) 53.1 17 
Physical Wellbeing 75 (64-92) 75.9 1 
Satisfaction with Information 84 (75-100) 82.5 2 
Satisfaction with Surgeon 100 (100-100) 95.9 2 
Satisfaction with Team 100 (100-100) 93.3 1 
Satisfaction with Office Staff 100 (93-100) 93.2 0 
 
 
  
Fig 1. Frequency distribution of time in weeks from surgery to radiotherapy 
 
  
Fig 2. Frequency distribution of time in weeks from surgery to chemotherapy 
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